What are the causes, symptoms, and appropriate treatment strategies for intestinal inflammation in women?

Intestinal Inflammation in Women: Causes, Symptoms, and Treatment

Women with inflammatory bowel disease (IBD) require aggressive disease control with continuation of most maintenance therapies, particularly during reproductive years, as active disease poses greater risks to maternal and fetal outcomes than the medications themselves. 1

Causes Specific to Women

Intestinal inflammation in women primarily manifests as IBD (Crohn's disease and ulcerative colitis), which affects women equally to men but presents unique considerations throughout reproductive life stages. 2, 3

Key causative factors:

• Autoimmune dysregulation with inappropriate immune responses to intestinal microbiota in genetically susceptible individuals 4
• Hormonal fluctuations during menstruation, pregnancy, and menopause may influence disease activity 3
• Women demonstrate increased eosinophil and mast cell activation in intestinal mucosa, contributing to barrier dysfunction and visceral hypersensitivity 5

Symptoms in Women

Common presentations include:

• Abdominal pain, diarrhea (often bloody in ulcerative colitis), and urgency 1
• Increased disease activity during menstruation in some women 3
• Perianal disease manifestations (fistulae, abscesses) particularly in Crohn's disease 1
• Extraintestinal manifestations affecting joints, skin, and eyes 6

Critical caveat: Women demonstrate higher disease activity rates compared to men despite receiving less immunosuppressive therapy, representing a significant treatment gap. 7

Treatment Strategies for Women

For Active Disease

Mild to moderate ulcerative colitis:

• Oral 5-ASA (mesalazine) 4g daily combined with rectal 5-ASA formulations for optimal mucosal contact 1
• Switch to 5-ASA formulations without dibutyl phthalate (DBP) in women of reproductive age 1

Mild to moderate Crohn's disease:

• Ileocecal disease: Budesonide 9mg daily for up to 12 weeks (better tolerated than systemic steroids but slightly less effective) 1
• Moderate to severe disease: Prednisolone 40mg daily, tapered over 8 weeks 1
• Consider early advanced therapy (anti-TNF biologics) for moderate-severe disease rather than repeated steroid courses 1

Severe disease requiring hospitalization:

• Intravenous hydrocortisone 400mg/day or methylprednisolone 60mg/day 1
• Concomitant IV metronidazole to distinguish active inflammation from septic complications 1
• For steroid-resistant flares: initiate anti-TNF therapy (infliximab 5mg/kg) 1

Perianal Crohn's disease:

• First-line: Metronidazole 400mg three times daily and/or ciprofloxacin 500mg twice daily 1
• Refractory cases: Anti-TNF therapy combined with surgical drainage 1

Maintenance Therapy

Critical principle: Continue maintenance medications throughout pregnancy as disease control is paramount. 1

Recommended maintenance regimens:

• 5-ASA therapy: Continue oral and/or rectal formulations 1
• Thiopurines (azathioprine 1.5-2.5mg/kg/day or mercaptopurine 0.75-1.5mg/kg/day): Continue throughout pregnancy 1
• Anti-TNF therapy: Continue throughout pregnancy; if discontinuation necessary for low-risk patients, administer last dose at 22-24 weeks gestation 1
• Lifelong maintenance recommended for all patients, especially those with extensive disease 1

Medication Contraindications in Women

Absolute contraindication:

• Methotrexate must be stopped at least 3 months before conception due to teratogenicity 1
• If pregnancy occurs on methotrexate: immediate discontinuation and urgent obstetric referral 1

Breastfeeding considerations:

• 5-ASA, corticosteroids, thiopurines, and anti-TNF therapy are compatible with breastfeeding 1
• Avoid methotrexate during breastfeeding 1

Special Considerations for Pregnancy

Preconception management:

• Mandatory preconception counseling for all women of reproductive age 1
• Objective disease assessment (endoscopy, imaging, biomarkers) before conception to optimize control 1
• Active disease at conception increases risks of prematurity (<37 weeks), low birth weight (<2500g), congenital abnormalities, cesarean delivery, spontaneous abortion, and neonatal death 1

Pregnancy monitoring:

• Gastroenterologist management throughout pregnancy 1
• High-risk obstetrics consultation for active or complicated disease 1
• Hospitalized patients require tertiary center transfer with gastroenterology and high-risk obstetrics access 1
• Anticoagulant thromboprophylaxis during hospitalization and post-cesarean delivery 1

Delivery planning:

• Base cesarean delivery decisions on obstetric indications, not IBD diagnosis alone 1
• Mandatory cesarean delivery for active perianal Crohn's disease to prevent perianal injury 1
• Consider cesarean delivery for women with ileal pouch-anal anastomosis (IPAA) to reduce anal sphincter injury risk 1

Diagnostic Approach During Pregnancy

Safe imaging modalities:

• Ultrasound and MRI preferred over radiation-based studies 1
• Flexible sigmoidoscopy or colonoscopy permitted when results will alter management 1

Common Pitfalls to Avoid

1. Undertreating women: Women receive significantly less immunosuppressive therapy than men despite higher disease activity—this treatment gap must be closed 7
2. Discontinuing medications during pregnancy: The risk of active disease far exceeds medication risks; maintain therapy 1
3. Delaying surgery: Urgent surgical intervention should not be postponed due to pregnancy 1
4. Inadequate disease control before conception: Achieve sustained remission before attempting pregnancy 1
5. Live vaccines in infants: Avoid live vaccinations in first 6 months of life for infants exposed to anti-TNF therapy in utero 1